At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 40 enrolled
Drug / intervention
E7080 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label, Multi-center, Roll-over Study to Assess Long Term Safety of Lenvatinib Monotherapy or Lenvatinib Combination Regimen or Comparator Treatment Arm to Cancer Patients in Eisai Sponsored Lenvatinib Trials
In Brief
A Phase 2 clinical trial evaluating E7080, Comparator Drug, and 1 other intervention for Solid Tumors. Completed, enrolled 40 participants across 28 sites in 11 countries.
Detailed Summary
This study will be conducted to assess the long-term safety of study drug(s) in participants who are enrolled in Eisai-sponsored lenvatinib studies.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSolid Tumors
CountriesAustralia, Belgium, China, Germany, Italy, Netherlands, Poland, Romania, South Korea, Thailand, United States
CollaboratorsMerck Sharp & Dohme LLC
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedMar 2018
Enrollment StartAug 2018
Primary CompletionDec 2023
TodayJul 2026
First PostedMar 26, 2018
Enrollment StartAug 16, 2018
Primary CompletionDec 21, 2023
TodayJul 2, 2026
Enrollment to primary: 5.3 yearsPosted 8.3 years ago
Interventions
E7080drug
Oral Administration.
Comparator Drugdrug
Per parent study.
Comparator Drug: Sorafenibdrug
Per parent study.